

Index

bold = table

- abdominal Xray, 115
- absolute neutrophil count (ANC), 199
- absorptive hypercalcemia, 153
- acral nerve roots, 235
- activities of daily living (ADLs), 102, 267
- acute carotid hemorrhage, 61
- acute coronary syndrome (ACS), 44, 51–55
 - diagnosis pearls, 52
 - HPI pearls, 52
 - invasive management, 54
 - management pearls, 53
 - mechanisms for development in cancer patients, 51
 - medical management, 55
 - pathophysiology, 51
 - pharmacologic management, 53
 - risk factors for cancer patients, 51
- acute hemolytic transfusion reaction, 57
- acute lymphocytic leukemia (ALL), 195, 207
- acute myeloid leukemia (AML), 185, 195, 207
- acute pain, 25–28
 - definition, 25
- acute pericarditis, 82–83
- acute promyelocytic leukemia (APL), 65, 185
- airway obstruction, 86
- airway symptom management
 - useful medications, 40
- alemtuzumab, 200
- alkaline phosphatase, 192
- alkylating agents, 5, 44, 156, 259
 - common arrhythmias, 48
 - heart failure as a side-effect, 67
 - vesicating chemotherapy agents, 169
- allogeneic HSCT, 7
- allograft recipients, 161
- all-trans retinoic acid (ATRA), 185
- American Society of Clinical Oncology, 91
- amoxicillin, 204, 221
- amylase, 123, 192
- analgesic effect, 27
- anemia, 49, 51, 63, 124, 136, 179, 265
 - ACS patients, 53
- anion gap, 119, 123
- anthracyclines, 44, 48
 - heart failure as a side effect, 67
 - vesicating chemotherapy agents, 169
- antibiotics, 58, 120, 124, 133, 187, 200, 203, 230, 247, 278
- antibody drug conjugates, 260
 - examples, 22
- anticancer agents
 - common arrhythmias associated with, 48
- anticancer treatment overview, 5
 - chemotherapy, 5–6
 - hematopoietic stem cell transplantation, 7–8
 - hormone therapy, 11
 - immunotherapy, 13–14
 - radiation therapy, 17–19
 - targeted cell therapy, 21–23
- anticholinergic medications, 39
- anticoagulation, 54, 92, 255, 256
- antiepileptic drugs, 250, 251
- antimetabolites, 5–6, 44, 48, 260
 - heart failure as side-effect, 67
- antimicrotubule agents, 5, 44, 48, 259
 - heart failure as side-effect, 67
- antimuscarinic medications, 39
- antiplatelet treatment, 53–54
- antipsychotics, 217
- antithrombotic prophylaxis, 49
- antitumor antibiotics, 5–6, 44, 259
- anxiety, 40
- apixaban, 93
- arm swelling, 86
- arsenic trioxide, 48, 185

Index

- ascites, 140, 192
 aspirin, 54, 55, 278
 atrial fibrillation (Afib), 47, 48, 49
 autoimmune diseases, 191
 autoimmune encephalopathy, 181
 autologous HSCT, 7
 axicabtagene ciloleucel, 14
- Bacillus Calmette-Guérin* (BCG)
 immunotherapy, 147, 150
- baclofen, 268
 bacteremia, 199–200
 bag valve mask (BVM), 270
 basic chemistry panel, 255, 264
 basic metabolic panel (BMP), 49, 63, 69, 79, 82, 102, 132, 148, 158, 162, 179, 201
 Beck's triad, 79
 beclomethasone, 193
 benign tumor
 definition, 1
 benzodiazepines, 40, 217, 250, 251
 beta-blockers, 181
 bevacizumab, 118, 122
 bilirubin, 140
 biologic response modifiers, 46
 bisphosphonates, 154
 BK virus, 147, 150, 161
 bladder cancer, 68
 bleeding, 54, 92
 main issue, 65
 bleomycin, 6, 44, 78, 81, 259
 blood flow stasis, 90
 blood pressure, 229
 blood products, 63, 66, 149
 blood transfusion complications, 57–59
 clinical presentation, 57
 imaging, 58
 incidence and mortality, 57
 laboratory analysis, 58
 onset, 57
 overview, 57
 pathophysiology, 58
 prevention, 58
 transfusion reaction workup, 58
 treatment, 58
 book purpose, xiii
 bowel infarction, 122, 123
 bowel necrosis, 132–133
 bowel perforation, 103, 118, 131–133, 178
- types, 117
 bowel wall, 97, 118, 119, 123
 brachytherapy, 17, 275
 bradycardia, 44–45, 92, 224
 brain cancer, 89
 brain damage, 223
 brain herniation, 224
 brain lesions, 248, 255
 brain metastasis, 235
 brain stem dysfunction, 224
 brain stem reticular formation, 105
 brain tumors, 250
 primary, 228
 brainstem herniation, 85
 breast cancer, 54, 68, 77, 153, 231, 243
 MBO rates, 113
 brexucabtagene autoleucel, 13–14
 brief confusion assessment method (bCAM), 216
 bronchiolitis obliterans, 192
 bronchoscopy, 265–266, 274, 275
 budesonide, 193
 bulk-forming agents, 99
 bulky symptomatic disease, 234
 Buza V, 49
- cachexia, 68, 98
 calcitonin, 154
 calcitrol, 153
 calcium chloride, 209
 calcium gluconate, 209
 cancer
 classes and groupings, 1
 complications (systems-based overview), 43–46
 definition, 1
 disseminated intravascular coagulation, 65–66
 most common types (2022), 2
 overview, 1–4
 survival rates, 3
 therapy (direct toxicity), 48
 treatment modalities, 3
 cancer-associated conditions
 cardiac involvement, 47
 cancer patients
 cancer patients with altered mental status, 211–212
 differential diagnosis, 211
 disposition, 212
 epidemiology, 211

- etiologies, 211
- etiology of pain, 26
- imaging, 212
- laboratories in ED, 211
- prothrombotic state, 89
- risk factors for ACS, 51
- risk factors, 211
- cancer related diarrhea (CRD),
 - 101–104
 - average ileostomy output, 103
 - causes, 101
 - definition, 101
 - diagnosis pearls, 103
 - HPI pearls, 102
 - medications, 104
 - pathophysiology, 102
 - severity assessment, 103
 - treatment, 103
- cancer treatment-induced arrhythmia (CTIA), 47–49
 - definition, 47
 - diagnosis pearls, 49
 - HPI pearls, 49
 - most common examples, 47
 - pathophysiology, 47
 - primary versus secondary, 47
 - treatment pearls, 49
 - types, 47
- capecitabine, 44, 48, 67, 101
- carboplatin, 44, 105, 156
- cardiac biomarkers, 69
- cardiac enzymes, 179
- cardiotoxicity, 6, 46, 68
 - rates (cancer patients), 43
- cardiovascular system, 47–49
 - acute coronary syndrome, 51–55
 - blood transfusion complications, 57–59
 - cancer treatment-induced arrhythmia, 47–49
 - carotid blowout syndrome, 61–64
 - disseminated intravascular coagulation, 65–66
 - heart failure, 67–70
 - hyperviscosity syndrome, 73–75
 - pericardial effusion, 77–80
 - pericarditis, 81–83
 - superior vena cava syndrome, 85–87
 - venous thromboembolism, 89–94
- cardiovascular disease (CVD), 43
 - complications caused by cancer treatments, 44
- carfuzomib, 48
- carotid blowout syndrome (CBS), 61–64, 264
 - categories, 61
 - definition, 61
 - diagnostic imaging, 63
 - HPI pearls, 62
 - impending or threatened (treatment), 64
 - incidence, 61
 - laboratory analysis, 63
 - mortality rate, 61
 - neurologic morbidity, 61
 - physical examination, 62
 - risk factors, 61
 - symptoms, 62
 - treatment, 63
 - treatment approaches (aggressive resuscitation), 63
 - treatment approaches (palliative care), 63
 - unstable, actively-bleeding patient (death within minutes), 63
- cauda equina syndrome, 232, 238
 - definition, 235
- cecal transmural inflammation, 131
- cecum, 131
- cefepime, 133, 203
- ceftazidime, 133
- celiac artery, 124
- cellulitis, 144, 201, 278, 279, 282
- cerebral ischemia, 223
- cerebral perfusion pressure (CPP), 224
- cerebrospinal fluid (CSF), 241, 245, 250
- cerebrovascular complications, 247
- cerebrovascular disease, 253
- cervical cancer, 144
- chance of death, 54
- chemotherapy, 75, 78, 81, 127, 131, 200, 207
 - CVD complications, 44
 - definition, 3
 - extravasation injury, 169
 - interstitial lung disease, 259
 - overview, 5–6
 - stroke in cancer patients, 253
 - types, 5
 - vesicating agents, 169
- chemotherapy agents, 147, 149

Index

- chemotherapy extravasation
 - management, 169–171
 - clinical assessment, 170
 - symptoms, 170
 - treatment, 170
- chemotherapy groups
 - types and mechanisms, 5
- chemotherapy treatment
 - mechanism for ACS development, 52
- chemotherapy-induced nausea and vomiting (CINV), 105–106
 - breakthrough (treatment options), 106
 - emetogenicity of chemotherapy agents, 106
 - pathophysiology, 105
 - risk factors (patient-specific), 106
 - risk factors (treatment-specific), 106
 - types, 105
- chest pain, 52, 53
- children, 244
- chimeric antigen receptor (CAR) T-cell, 49
- chimeric antigen receptor (CAR) T-cell therapy, 14, 14, 46, 247
 - process, 14
- chimeric antigen receptor T-cell toxicity (CARTOX), 173–176
 - side-effect syndromes, 173
- chlorhexidine, 128
- chlorpromazine, 217, 268
- chronic gastrointestinal pseudo-obstruction, 244
- chronic lymphocytic leukemia (CLL), 195
- chronic myeloid leukemia (CML), 195
- chronic obstructive pulmonary disease, 203
- chronic oxygen therapy, 68
- chronic pain
 - definition, 25
- Chvostek sign, 208
- ciprofloxacin, 204, 247
- cisplatin, 48, 105–106
- clavulanate, 204
- clindamycin, 204, 204
- Clinical Index of Stable Febrile Neutropenia (CISNE), 203
- clofarabine, 48
- clonazepam, 251
- clopidogrel, 54, 278
- clotting
 - main issue, 65
- CNS, 25, 65, 73, 93, 196, 231, 245, 248, 267
- CNS infections, 247
- coagulation cascade, 90, 228
- coagulation studies, 264
- coagulopathy, 63, 119, 120, 123, 124, 133, 149, 187, 229, 255, 256, 265
 - stroke in cancer patients, 253
- codeine, 26, 30
- colchicine, 83
- colitis, 103
- collagen, 136
- collagen vascular disorders, 191
- colon cancer, 54, 101, 117
- colonoscopy, 136
- communication tips
 - delivering bad news, 35
- complete blood count (CBC), 49, 63, 69, 79, 82, 264
- complete metabolic panel, 74, 119, 123, 136, 140, 186, 192, 196
- computed tomography (CT), 86, 180, 239
- computed tomography angiography (CTA), 63, 70, 123, 166, 255
- computed tomography pulmonary angiography (CTPA), 91
- conditioning therapy, 14
- constipation, 97–99, 114
 - definition, 97
 - diagnosis pearls, 98
 - etiology in cancer patients, 98
 - HPI pearls, 98
 - pathophysiology, 97
 - pharmaceutical bowel cleansing, 99
 - related symptoms, 98
 - Rome criteria, 97
 - treatment, 98
- constrictive pericarditis, 82
 - clinical presentation, 81
 - etiology, 81
- contrast extravasation, 63
- conus medullaris, 237–239
- coronary artery bypass grafting (CABG), 53, 55
- coronary artery disease (CAD), 51
- coronary artery vasospasm, 53
- corticosteroids, 175, 192, 240

- COVID-19, **180**
- cranial nerves, **232**
- cranial neuropathies, **232**
- cranial radiation, **247**
- cranial vault
 components, **223**
- craniotomy, **247**
- creatinine, **161, 179**
- Cryptococcus, **247**
- Cushing's Triad, **224**
- CXR, **79, 86**
- cyclin-dependent kinase inhibitor, **21**
- cyclophosphamide, **105–106, 147, 149, 157, 181**
- cyclosporine, **181, 193, 250**
- cystoscopy, **149**
- cytokine release, **259**
- cytokine release syndrome (CRS), **49**
 common terminology criteria for
 adverse events (version 5.0), **173**
 death risk, **175**
 description, pathophysiology,
 clinical presentation, onset,
 duration, diagnosis pearls, **173**
 grading and treatment, **174**
- cytokines, **68, 90, 139, 153, 185, 196**
- cytology, **233, 250**
- cytomegalovirus, **9, 189**
- cytopenia, **133**
- dabigatran, **93**
- dalteparin, **93**
- D-dimer, **66, 90, 92, 196**
- death rattle, **39**
- deep vein thrombosis (DVT), **89, 144**
 imaging, **91**
 mortality risk, **90**
 symptom presentation, **90**
- defibrotide, **140**
- dehydration, **74, 114, 136**
- delirium, **215–218**
 definition, **215**
 diagnosis, **215**
 etiology in cancer patients, **215**
 incidence, **215**
 key diagnostic features, **216**
 screening in ED, **216**
 symptom management, **217**
 treatment, **217**
 types, **215**
- delirium triage screen (DTS), **216**
- delivering bad news, **35**
- cancer patient preferences, **35**
- SPIKES 6-step protocol, **35**
- depression
 antidepressant medications and
 drug interactions, **220**
 cancer patients, **219–221**
 diagnosis, **219**
 drug interactions (examples), **221**
 incidence, **219**
 increases cancer mortality rates, **219**
 screening in ED (In SAD CAGES
 mnemonic), **220**
- dermatomyositis, **244**
- dexamethasone, **175, 187, 207, 229, 240**
- dexrazoxane, **170**
- diabetes, **55**
- Diagnostic and Statistical Manual, **216, 220**
 depression diagnosis criteria, **219**
- diazepam, **41, 251**
- differentiation agents, **45**
- differentiation syndrome
 definition, **185**
 occurrence, **185**
- differentiation syndrome in acute
 leukemias, **185–187**
 clinical presentation, **185**
 diagnostic imaging, **186**
 ED management, **186, 187**
 features, **185**
 laboratory evaluation, **186**
 pathophysiology, **185**
 severity grading, **185**
 symptoms, **185**
 treatment, **187**
- diplopia, **232, 250**
- direct factor Xa inhibitors, **93**
- direct oral anticoagulants (DOACs),
 91, 93
- direct thrombin inhibitors, **93**
- disseminated intravascular coagulation
 (DIC), **65–66, 195, 196, 255**
 clinical presentation in cancer
 patients, **65, 65**
 course, **65**
 definition, **65**
 laboratory diagnosis, **66**
 treatment, **66**
 types, **65**
 worsening values (importance), **66**
- docetaxel, **118**

Index

- dopamine, 105
 dysarthria, 232
 dysphagia, 85, 232
 dyspnea, 40, 52, 78, 81, 179, 261
 symptom of SVC syndrome, 86
 dysuria, 148, 161
- echocardiogram, 68, 79, 82, 92
 echo-guided pericardiocentesis, 79
 edema, 176
 airway, 85
 cerebral, 85–86, 229
 excessive, 229
 lower extremity, 69
 peripheral, 79, 81
 periportal, 192
 sacral, 69
 spinal cord, 236, 240
 vasogenic, 229
- EEG, 249
 EKG, 49, 52, 55, 69, 79, 82, 186, 208
 electrolyte abnormalities, 265
 electrolyte replacement, 192
 electrolyte secretion, 101
 elevated intracranial pressure (ICP),
 223–225, 232, 234
 brain herniation (physical
 examination findings), 224
 clinical symptoms, 224
 definition, 223
 diagnostic imaging, 224
 etiologies, 223
 management, 224
 occasion, 223
- ematopoietic stem cell transplantation
 (HSCT)
 cancers treated by, 8
- Emergency Department
 initial opiate doses, 27
 opiates utilized, 26
 pain and palliative care, 25–28
 pain management, 26
 statistics, 3
- emergency physicians (EPs)
 delivering bad news, 35
- emesis, 105
 emetic center triggering, 106
 empathy, 36
 empyema, 278–279
 encephalitis, 246
 encephalomyelitis, 243
 encephalopathy, 173, 254
 endocrine abnormalities, 49
 endocrinopathy, 182
 end-of-life symptom management,
 39–41
 non-pharmacological management,
 39
 endometrial cancer, 144
 endoscopy, 62, 136
 endothelial damage, 52, 196
 endothelial injury, 90
 endothelium, 140
 endotracheal intubation, 275
 endotracheal tube (ETT), 63, 265
 endovascular stenting, 87
 endovascular thrombectomy
 treatment, 255
 enema, 98
 enoxaparin, 93, 278
 Enterobacteriaceae, 279
 enzymatic declogging agents, 110
 epidural compression, 235
 epidural hemorrhage (EDH), 227
 epidural space, 236
 epidural tumor, 241
 epilepsy
 frequency (based on type of brain
 tumor), 248
 epinephrine, 266
 epistaxis, 62
 epithelial cells, 135
 epithelium loss, 102
 Epstein Barr virus seropositivity, 189
 equianalgesic dose
 definition, 29
 equianalgesic dosing steps, 29
 erythema, 127, 170, 279
 esophageal perforation, 118
 excessive secretions, 40
 exercise tolerance, 68
 external beam radiation, 17
 extravasation
 definition, 169
- facial nerve, 232
 facial swelling, 86
 FDA, 21, 140, 268
 febrile non-hemolytic transfusion
 reaction, 57
 feeding tube complications, 109–111
 accidental feeding tube removal, 110

- clogged long-term feeding tube, 110
- steps to reinsert feeding tube, 110
- troubleshooting, 110
- types, **109**
- feeding tubes (types), **109**
- fentanyl, **26, 30, 34**
 - initial ED doses, **27**
- fentanyl patch strength, **30**
- fentanyl transdermal patch, **27**
- fever
 - definition, **199**
- fibrinogen, **66, 196, 229, 255**
- fibrinolytic treatment, **255**
- fibronectin, **136**
- fistula development, **145**
- five-fluoro-uracil (5-FU), **6, 44, 48, 67**
- FLAIR images, **245**
- flow cytometry, **250**
- fludarabine, **48, 200**
- fluoroquinolone, **204**
- fluorouracil, **102**
- fractionation regimens, **18**
- fulgration, **149**

- GABA agonist, **181**
- gabapentin, **240, 268**
- gadolinium, **249**
- gamma knife surgery, **17**
- gastrointestinal system, **140**
 - cancer related diarrhea, **101–104**
 - chemotherapy-induced nausea and vomiting, **105–106**
 - constipation management, **97–99**
 - feeding tube complications, **109–111**
 - malignant bowel obstruction, **113–115**
 - malignant intestinal perforation, **117–120**
 - mesenteric bowel ischemia, **121–125**
 - mucositis, **127–128**
 - neutropenic enterocolitis, **131–133**
 - radiation enteritis, **135–137**
 - sinusoidal obstruction syndrome, **139–140**
- gastrointestinal malignancies, **231**
- gastrointestinal tract lymphoma, **117**
- gemcitabine, **48, 122**
- general statistics, **2**
- genetic engineering, **14**
- genetically modified T-cells, **14**
- genitourinary system, **143–145**

- gynecologic oncology surgery
 - complications, **143–146**
 - hemorrhagic cystitis, **147–151**
 - hypercalcemia, **153–154**
 - hyponatremia, **155–159**
 - obstructive uropathy in cancer patients, **161–163**
 - percutaneous nephrostomy (PCN) tubes, **165–166**
- gilteritinib, **185**
- glioblastoma multiforme, **228**
- glucocorticoids, **240**
- glycopyrrrolate, **40**
- Gottron's papules, **244**
- graft versus host disease (GvHD), **9, 57, 189–193, 200**
 - clinical presentation, **190–191**
 - computed tomography (CT) findings, **192**
 - definition, **189**
 - ED management, **192**
 - four clinical groups, **189**
 - incidence, **189**
 - laboratory analysis, **191**
 - pathophysiology, **190**
 - radiologic findings, **192**
 - risk factors, **189**
 - severity grades, **190–191**
 - treatment, **192**
 - types (acute versus chronic ~), **189**
- Guillain-Barré Syndrome, **181**
- gynecologic cancers
 - types, **143**
- gynecologic oncology surgery
 - complications, **143–146**
 - considerations, **144**
 - enterovaginal fistula, **146**
 - fistula development, **145**
 - surgical site infections, **144**
 - vesicovaginal fistula, **146**
- gynecological surgeries and procedures, **143**

- haloperidol, **106, 217**
- HDAC inhibitors, **48**
- head and neck cancer, **61, 156, 264**
- hearing loss, **232**
- heart failure (HF), **44, 67–70**
 - comorbidity in cancer patients, **68**
 - definition, **67**
 - diagnostic imaging pearls, **70**

Index

- heart failure (HF) (cont.)
 - HPI pearls, 68
 - laboratory analysis, 69
 - management pearls, 70
 - physical examination pearls, 69
 - side effect of anticancer treatment, 67
- heat moisture exchange (HME), 270
- hematemesis, 62, 263
- hematochezia, 132
- hematologic cancers
 - drugs, 14
 - frequent causes of ICH, 228
- hematomas, 149, 227–228, 270
- hematopoietic stem cell
 - definition, 7
- hematopoietic stem cell transplantation (HSCT), 7–8, 127, 139, 147, 199
 - classification by graft source, 7
 - complications, 8, 189
 - definition, 7
 - types, 7
- hematuria, 148, 148, 149, 150, 161, 162, 166
- hemodialysis, 154
- hemoptysis, 62, 263–266
 - definition, 263
 - diagnosis, 264, 264
 - imaging, 264
 - immediate post-intubation treatments, 266
 - initial evaluation and HPI pearls, 263
 - laboratory workup, 264
 - minor versus massive, 263
 - mortality rate, 263
 - pathogenesis, 263
 - securing airway, 265
 - treatment pearls (massive ~), 265
- hemorrhage
 - mortality risk, 65
- hemorrhagic cystitis, 147–151
 - clinical presentation, 148
 - definition, 147
 - diagnosis, 148
 - ED management, 149
 - etiology, 147
 - imaging, 148
 - laboratory analysis, 148
 - medications for symptom control, 149
 - severe bleeding, 149
 - specific treatment, 149
- hemorrhagic stroke, 254, 256
- hemostasis, 61, 266
- heparin, 54, 66, 278
- hepatic enzyme function, 250
- hepatitis, 179
- hepatocytes, 139
- hepatomegaly, 140, 192
- herniation, 224, 256
- herniation risk, 223, 250
- hiccups, 267–268
 - categories (symptom duration), 267
 - definition, 267
 - etiology in cancer patients, 267
 - medications, 268
 - pathophysiology, 267
 - treatment, 268
- histamine, 26, 105
- histocompatibility differences, 189
- Hodgkin's lymphoma, 44
- hormone therapy, 11
 - CVD complications, 45
 - definition, 4, 11
 - examples, 11
 - overview, 11
- HTN. *See* hypertension
- human herpes virus, 247
- humoral hypercalcemia, 153
- hyaluronidase, 170–171
- hydration, 192, 209
 - intravenous (IV), 79
- hydrocephalus, 256
- hydrocodone, 26, 27, 30
- hydromorphone, 26, 27, 30, 34
 - initial ED doses, 28
 - large initial doses to be avoided in opiate naïve patients, 28
- hydroxyurea, 197
- hypercalcemia, 153–154
 - calcitonin dose, 154
 - diagnosis, 154
 - EKG findings, 154
 - first line treatment (IVF hydration), 154
 - management, 154
 - mechanisms, 153
 - median time for survival, 153
 - pathophysiology, 153
 - potentially life-threatening, 153
 - presentation, 153

- hypercoagulability, **90**
hypercoagulable state, **121, 253**
hyperfibrinolytic DIC, **65–66**
hyperfractionation, **18**
hyperglycemia, **203**
hyperkalemia, **208–209**
hyperkalemic non-anion gap metabolic acidosis, **162**
hyperleukocytosis, **195–197**
 definition, **195**
 management, **197**
hyperphosphatemia, **208**
hyperreflexia, **239**
hypertension (HTN), **44, 55, 224**
hyperthyroidism, **181**
hyperuricemia, **208–209**
hyperviscosity syndrome, **73–75**
 bleeding, **74**
 clinical findings, **74**
 definition, **73**
 diagnosis, **74**
 emergency department management, **74**
 laboratory analysis, **74**
 pathophysiology, **73**
 treatment, **74**
hypoalbuminemia, **192**
hypocalcemia, **208–209**
hypofractionation, **18**
hyponatremia, **155–159, 162**
 acute versus chronic, **157**
 cancer therapy causing, **156**
 cancers causing, **156**
 clinical presentation, **157**
 definition, **155**
 diagnosis, **157**
 etiology (four categories based on sodium balance), **155**
 HPI pearls, **157**
 outcomes, **155**
 pathophysiology, **155**
 severity levels, **155**
 SIADH criteria, **158**
 symptoms, **155, 157**
 treatment (direct versus indirect modality), **158**
hypoperfusion, **73, 121, 123**
hypophysitis, **180, 181**
hyposplenism, **200**
hypotension, **52, 79, 132, 173, 173, 187**
hypothyroidism, **181, 182**
hypovolemia, **79**
hypoxemia, **195, 261**
hypoxia, **174**
hysterectomy, **143, 145**
ifosfamide, **44, 67, 106, 147, 156**
immunotherapy, **81**
ileal conduit, **143, 145**
ileal orthotopic neobladder, **143, 145**
ileum, **131**
imipenem-cilastin, **133**
immune checkpoint inhibitors (ICI), **13, 46, 49, 83, 102, 177, 260**
 heart failure as side-effect, **68**
immune effector cell associated neurotoxicity (ICANS)
 description, pathophysiology, clinical presentation, onset, duration, diagnosis pearls, **173**
 grading and treatment, **175**
immune effector cell-associated encephalopathy (ICE), **175**
immune related adverse events (irAEs), **14, 177–182**
 death risk, **178**
 diagnostic imaging pearls, **180**
 disposition, **182**
 endocrine ~ (treatment), **182**
 HPI pearls, **178**
 immunosuppression, **181**
 inflammatory, **180**
 laboratory tests, **179**
 most common types (in ED), **177**
 organ system toxicity, **180**
 overview by system, **178**
 terrible triad, **177, 179, 181**
 treatment pearls, **181**
 universal toxicity grade overview, **177**
immunomodulatory drugs, **48**
immunosuppression, **57, 118, 131, 181, 193, 246, 247, 259**
immunotherapy, **13–14, 78, 207**
 CVD complications, **46**
 definition, **4**
 overview, **13**
immunotherapy treatment
 mechanism for ACS development in cancer patients, **52**
induction chemotherapy, **197, 199**
induration, **279**

Index

- indwelling Foley catheter, 163
indwelling pulmonary catheter (IPC), 279
infliximab, 181
inotropic medication, 79
intensity-modulated radiation therapy (IMRT), 17
interleukin-6 (IL-6), 173, 175
interstitial lung disease
 chemotherapy, 259
 clinical picture, 259
 definition, 259
 immunotherapy, 260
 induced by cancer treatment, 259–261
 radiation pneumonitis, 261
 targeted therapy, 260
interstitial therapy, 17
intestinal mucosa, 131
intracranial hemorrhage (ICH), 255
 cancer patients, 227–230
 causes (less frequent and rare), 227
 coagulopathy correction, 229
 diagnosis, 228
 imaging, 228
 laboratory analysis, 229
 management, 229
 most common types, 227
 patient presentation, 228
 symptoms, 228
 tumor types and likelihood of, 228
 types, 227
intracranial hypertension, 224
intraoperative radiotherapy, 17
intraparenchymal hemorrhage (IPH), 227
intraperitoneal contamination, 117
intratumoral hemorrhage, 229
intravenous immune globulin, 246
irinotecan, 6, 106
irinotecan early (and late) onset
 diarrhea
 definitions, 102
irritable bowel syndrome, 97
ischemia, 11, 47, 61, 65, 82, 118, 169, 195
ischemic stroke, 254, 256
 comorbidity with cancer, 253
isocitrate dehydrogenase, 185
ivosidenib, 185
jaundice, 69
jugular venous distention (JVD), 69, 79
Kernohan's notch phenomenon, 224
kidney, 162–163, 165, 203
Kinsbourne syndrome, 244
lactic acid, 123, 132, 186, 192, 201
Lambert–Eaton Myasthenic Syndrome (LEMS), 244, 246
laryngectomy
 airway management, 270
 complications, 269–271
 definition, 269
 indications, 269
 potential complications (overview), 270
 tubes and devices, 270
 versus tracheostomy, 269
lenalidomide, 46, 48
leptomeningeal disease (LMD), 231–234, 250
 altered mental status, 232
 cerebellar dysfunction, 232
 clinical features, 231
 definition, 231
 diagnosis, 233
 evaluation, 231
 gadolinium-enhanced MRI of brain and spine, 233
 HPI pearls, 231
 incidence, 231
 lumbar puncture, 233
 mortality, 231
 pathophysiology, 231
 physical examination, 231
 plateau waves, 233
 seizures, 233
 source tumors (most common), 231
 supportive care needs, 234
 symptoms, 231
 treatment, 233
leptomeningeal metastases, 245
leptomeninges, 231
leukapheresis, 14, 197
leukemia, 73, 77, 199
leukocytes, 197
leukocytosis, 119, 146
leukostasis, 195–197
 clinical presentation, 196
 definition, 195

- definitive management, 197
- diagnostic imaging, 197
- ED management, 197
- laboratory analysis, 196
- pathophysiology, 195
- treatment, 197
- levothyroxine, 182
- Levy's rule, 30
- Lhermitte phenomenon, 239
- life expectancy, 163
- Ligament of Treitz, 113
- limbic encephalitis, 243, 245
- lipase, 119, 123, 132, 180, 192
- liver, 139, 192
- liver cancer, 89, 156
- liver disease, 139
- liver function tests, 179
- loperamide, 104
- lorazepam, 41, 251
- low molecular weight heparin (LMWH), 91, 93, 256
- lumbar nerve roots, 235
- lumbar puncture (LP), 233, 245, 250, 254
- lumbosacral lesions, 236
- luminal bacteria, 135
- lung cancer, 54, 68, 77, 117, 153, 156, 231
 - associated with ACS, 51
- lung cancer patients
 - MCAO complications, 273
- lymph node removal, 143
- lymphangitis, 145
- lymphatic system, 173–176
 - chimeric antigen receptor T-cell toxicity, 173–176
 - differentiation syndrome in acute leukemias, 185–187
 - graft versus host disease, 189–193
 - hyperleukocytosis and leukostasis, 195–197
 - immune related adverse events, 177–182
 - neutropenic fever, 199–204
 - tumor lysis syndrome, 207–209
- lymphedema
 - definition, incidence, symptom management, 144
- lymphocyst
 - definition, symptoms, risks, 144
- lymphocyte function, 200
- lymphoma, 86, 101, 243
- magic mouthwash, 128
- magnesium citrate, 99
- magnetic resonance imaging (MRI), 212, 233, 239
 - brain, 229
 - paraneoplastic syndromes, 245
 - pituitary protocol, 180
- malignant bowel obstruction (MBO), 113–115
 - clinical presentation, 114
 - definition, 113
 - diagnosis, 113–114
 - ED management, 115
 - endoscopic palliation and stent, 115
 - life expectancy, 113
 - origination of obstruction, 113
 - pathophysiology, 114
 - percutaneous endoscopic gastrostomy, 115
 - results, 114
 - surgical management, 115
 - treatment, 115
 - tumor factors leading to, 114
- malignant central airway obstruction (MCAO), 273–275
 - definition, 273
 - diagnostic imaging, 274
 - ED management, 274
 - etiology, 273
 - incidence, 273
 - physical examination pearls, 274
 - symptoms, 273
 - types, 273
- malignant intestinal perforation, 117–120
 - cancer types associated with, 118
 - cancer-related risk factors, 117
 - clinical presentation pearls, 118
 - definition, 117
 - diagnostic imaging, 119
 - ED management, 120
 - laboratory analysis, 119
 - pathophysiology, 118
 - side-effect risk of cancer treatments, 118
 - types, 117
- malignant pleural effusion (MPE), 277–280
 - cancers causing, 277
 - chemical pleurodesis, 278
 - definition, 277

Index

- malignant pleural effusion (MPE) (cont.)
 definitive management, 278
 dislodgement, 279
 guidelines prior to pleural interventions, 278
 indwelling pulmonary catheter, 278, 278
 infection risk, 278
 initial treatment, 277
 occlusion, 279
- malignant spinal cord compression (MSCC), 235–241
 autonomic dysfunction, 237
 clinical features, 236
 consultations (key) in ED, 240
 definition, 235
 diagnostic imaging, 239
 ED management, 240
 epidemiology, 235
 glucocorticoids, 240
 HPI pearls, 238
 motor findings, 237
 neurologic impairment, 237
 pain, 236, 238, 240
 pathophysiology, 235
 physical examination findings, 238
 prognosis, 241
 sensory findings, 237
 sensory loss, 239
 testing for mechanical instability, 239
 treatment, 240
 weakness, 238
- malignant tumor
 definition, 1
- MD Anderson Cancer Center, xiii, 229, 240
- medial temporal lobes, 245
- mediastinal radiotherapy, 52
- mediastinitis, 119
- medulla oblongata, 105
- melanoma, 231, 247
 MBO rates, 113
- melena, 132
- melphalan, 48
- meningioma, 228
- mental status, 69
- mesenteric artery embolus, 124
- mesenteric artery thrombosis, 124
- mesenteric bowel ischemia, 121–125
 cancer-related risk factors, 121
 clinical presentation, 122
 definition, 121
 diagnosis, 123
 ED management, 124
 laboratory analysis, 123
 mortality rate, 121
 onset, etiology, pathogenesis, 121
 radiologic findings, 123
 types, 121
- mesenteric thrombosis, 114, 124
- metabolic acidosis, 119, 123
- metabolic derangement, 68
- metabolites, 43, 68
- metastasis, 47
 cancer-specific locations, 2
 definition, 1
 routes and definitions, 2
- metastatic brain tumors, 248
- metastatic cancer, 117, 235
- methotrexate, 6, 101, 106, 156, 181, 247, 253, 260
- methylprednisolone, 40, 83, 176, 193, 246
- metocloperamide, 107
- metronidazole, 133
- microvasculature endothelium, 135
- midazolam, 41, 251, 251
- monoclonal antibodies, 21, 22, 45, 260
 types and mechanisms, 22
- monoclonal antibody-based tyrosine kinase inhibitors
 heart failure as side-effect, 67
- monocytes, 203
- Monro-Kellie Doctrine, 223
- morphine, 26, 27, 29, 30, 34, 40
 initial ED doses, 27
 Standard IV ~ bolus dose, 27
- morphine (oral) to methadone
 conversion table, 30
- morphine sulfate mouthwash, 128
- mortality risk, 54, 90
- Morvan's syndrome, 243
- MRSA, 278
- mTOR inhibitors, 260
- mucositis, 127–128, 135, 200, 203
 clinical presentation, 127
 definition, 127
 incidence in cancer patients, 127
 oral ~ assessment scale, 128
 treatment options, 128

- multifocal hemorrhages, 228
- Multinational Association for Supportive Care in Cancer (MASCC), 202
- multiple myeloma, 73, 89, 153
- myalgia, 78, 173, 178
- myasthenia gravis (MG), 178, 181, 246
 - high morbidity and mortality, 177
- mycophenolate mofetil, 181
- myeloid cells, 185
- myocarditis, 82, 178–179
 - high morbidity and mortality, 177
- myopericarditis, 82
- myositis, 178–179
 - high morbidity and mortality, 177
- naked monoclonal antibodies
 - examples, 22
- National Cancer Institute Grading Scale, 103
- National Comprehensive Cancer Network, 91
- necrosis, 62–63, 109, 118
- necrotic degeneration, 118
- nephrolithiasis, 162
- nervous system, 256
 - delirium, 215–218
 - depression, 219–221
 - elevated intracranial pressure, 223–225
 - intracranial hemorrhage, 227–230
 - leptomeningeal disease, 231–234
 - malignant spinal cord compression, 235–241
 - paraneoplastic syndromes, 243–246
 - seizure management, 248–251
 - stroke, 253–256
- neural foramina, 236
- neuroblastoma, 244
- neuroendocrine tumor, 101, 243
- neuroimaging, 176, 229, 255
- neurokinin, 105
- neuropathy, 181
- neutropenia
 - definition, 199
- neutropenic enterocolitis, 131–133
 - antimicrobial therapy, 133
 - clinical presentation, 131
 - complications, 131
 - definition, 131
 - diagnostic imaging, 132
 - incidence, 131
 - laboratory analysis, 132
 - medical management, 133
 - pathophysiology, 131
 - surgical management, 133
 - symptoms, 131
 - treatment, 133
- neutropenic fever (NF), 199–204
 - diagnostic imaging pearls, 202
 - disposition, 204
 - factors altering immune system function, 200
 - factors increasing risk of infection, 200
 - HPI pearls, 200
 - incidence, 199
 - initial antibiotic choice, 203
 - laboratory tests, 201
 - microbiology, 200
 - mortality (true emergency), 199
 - pathophysiology, 200
 - patient stratification (high-risk versus low-risk), 202
 - physical examination pearls, 201
- nitrogen mustard, 44
- non-convulsive status epilepticus (NCSE), 249
- non-Hodgkin's lymphoma, 207
- non-occlusive ischemia, 124
- non-ST segment elevation myocardial infarction (NSTEMI), 51–52, 54, 69
- norepinephrine, 266
- NSAIDs, 27, 83
- nuchal rigidity, 232
- obstructive uropathy, 161–163
 - clinical presentation, 161
 - diagnostic imaging, 162
 - etiology, 161
 - laboratory analysis, 162
 - nondilated, 162
 - treatment, 162
- octreotide, 104
- olanzapine, 217, 221
- oligodendrogliomas, 228
- omentectomy, 143
- opiate equianalgesic conversion, 29–31
- opiate rotation (indications), 29
- opiate-naïve patient, 27–28
- opiate-tolerant patient, 27–28

Index

- opioid equivalency table, 30
- opsoclonus–myoclonus
 - definitions, 244
- oral candidiasis infection, 128
- oral morphine to methadone
 - conversion table, 30
- oral mucositis
 - assessment scale, 128
 - treatment options, 128
- oropharyngeal bleeding, 263
- oropharynx, 39
- orthopnea, 57, 79, 273
- osmotic diarrhea, 102
 - definition, 101
- osmotic laxative, 99
- osteolytic metastases, 153
- otolaryngology, 62
- ovarian cancer, 144, 243
 - concomitant VTE diagnosis, 144
- oxycodone, 26, 27, 30
 - initial ED doses, 27
- oxygen, 86
- oxygenation, 187
- oxymorphone, 30

- P. jirovecci, 9
- paclitaxel, 5, 44–45, 48, 259–260
- pain
 - categorization based on mechanism, 25
 - definition, 25
 - etiology in cancer patients, 26
 - opiates used in ED, 26
- pain and palliative care in the
 - Emergency Department, 25–28
 - acute pain management, 25–28
 - communication tips for delivering bad news, 35
 - end of life symptom management, 39–41
 - opiate equianalgesic conversion, 29–31
 - patient controlled analgesia pump, 33–34
- pain assessment considerations, 26
- palliative sedation, 41
- pancoast tumors, 47
- pancreatic cancer, 89, 101, 156
- pancreatitis, 180
- pancytopenias, 8
- panic, 40

- panobinostat, 48
- papilledema, 74, 196, 232, 234
- paraneoplastic limbic encephalitis, 247
- paraneoplastic neuropathy, 114
- paraneoplastic syndromes (PNS), 243–246
 - antibodies (types), 245
 - definition, 243
 - diagnosis, 245
 - electrophysiology, 245
 - MRI, 245
 - treatment, 246
 - types, 243
- paraproteins, 73
- parenchymal brain hemorrhage, 247
- parenteral administration, 27
- paresthesia, 232, 237–238
- pathophysiology, 13
 - cardiovascular events in cancer patients, 43
- patient-controlled analgesia
 - initiation orders in ED, 34
- patient-controlled analgesia pump, 34
 - contraindications, 33
 - definition, 33
 - programmable settings, 33
- pelvic exenteration, 143, 145
- penicillin, 204, 204
- perception, 36
- percutaneous coronary intervention (PCI), 53, 54, 55
- percutaneous nephrostomy, 163
- percutaneous nephrostomy (PCN)
 - tubes
 - complications, 165
 - placement (general indications), 165
 - troubleshooting, 165–166
- pericardial chest pain, 82
- pericardial effusion, 77–81, 186
 - cancer treatment side-effect, 78
 - definition, 77
 - diagnosis pearls, 79
 - etiology, 77
 - hemodynamically unstable patients, 79
 - hemodynamically-stable patients
 - without hypotension, 80
 - HPI pearls, 78
 - malignancy, 77
 - other causes, 78
 - pathophysiology, 78

- physical examination pearls, 79
- symptoms, 78
- treatment pearls, 79
- pericardial friction rub, 82
- pericardial tamponade (PT), 79
 - definition, 77
 - malignant, 79
- pericardiocentesis, 79
- pericarditis
 - clinical diagnosis, 82
 - definition, 81
 - diagnosis pearls, 82
 - etiology in cancer patients, 81
 - HPI pearls, 82
 - physical examination pearls, 82
 - treatment, 83
- pericardium
 - cancer types that invade, 77
- pericarditis, 81–83
- peripheral nervous system, 245
- peritoneal carcinomatosis, 113
- peritoneal contamination, 120
- peritoneal infiltration, 113
- peritoneum, 113
- peritonitis, 119
- pheochromocytoma, 101
- phrenic nerve, 82, 267
- piperacillin-tazobactam, 133, 203
- plant alkaloids, 5
- plasma exchange, 246
- plasma osmolality, 158
- plasmapheresis, 74
- platelets, 53, 54
 - aggregation time, 73
 - disseminated intravascular coagulation, 66
- platinum compounds, 44, 156
- platinum-based chemotherapy regimens, 122
- pleocytosis, 233
- pneumatosis, 118, 123, 132
- pneumomediastinum, 119
- pneumonia, 192
- pneumoperitoneum, 119
- point of care testing, 119
- polyethylene glycol, 99
- polymicrobial sources, 200
- posterior reversible encephalopathy syndrome, 247
- post-nephrostomy pyelonephritis, 165
- prednisone, 181, 193, 261
- premature atrial complex (PAC), 48
- primary brain tumors, 248
- proangiogenic factors, 90
- prochlorperazin, 107
- procoagulant DIC, 65–66
- promethazine, 107
- propofol, 41
- proprioceptive loss, 237
- prostate cancer, 54, 68, 156
- proteasome inhibitors, 45, 48
 - heart failure as side-effect, 67
 - substem, 21
- prothrombin time, 140
- prothrombotic state, 89
- pseudoaneurysm, 61, 63
- Pseudomonas aeruginosa*, 279
- ptosis, 179, 224
- pulmonary crackles or rales, 69
- pulmonary embolism, 264, 277
 - imaging, 91
 - mortality risk, 90
 - risk stratification, 92
 - symptom presentation, 90
- pulmonary fibrosis, 192
- pulse oximetry, 92, 196
- pulsus paradoxus, 79
- pyridostigmine, 181
- QTc prolongation and other repolarization abnormalities, 47
- quality of life, 97, 101, 163, 233, 278
- quetiapine, 217
- radiation enteritis, 135–137
 - acute versus chronic, 135
 - clinical presentation, 136
 - complications, 137
 - definition, 135
 - diagnosis, 136
 - ED treatment, 136
 - pathophysiology, 135
 - risk factors, 135
- radiation pneumonitis, 261
 - clinical presentation, 261
 - death risk, 261
 - grading scale, 261
 - incidence, 261
 - pulmonary function testing, 261
 - treatment, 261

Index

- radiation therapy (RT), 17–19, 49, 81, 86, 147, 149, 207, 234, 236, 241
 - CVD complications, 44
 - delivery modes, 17
 - heart failure as side-effect, 68
 - mechanism for ACS development in cancer patients, 52
 - overview, 17
- radicular pain, 236, 238
- radiculopathy, 232
- radiogenic fibrosis, 114
- radiographic imaging, 103
- radiotherapy, 48, 78, 105, 127
 - definition, 3
- radiotherapy intention
 - types, 18
- rasburicase, 209
- refractory dyspnea, 39
- renal cancer, 153, 156
- renal ultrasound, 162
- respiratory system, 283
 - hemoptysis, 263–266
 - hiccups, 267–268
 - interstitial lung disease (induced by cancer treatment), 259–261
- laryngectomy complications, 269–271
- malignant central airway obstruction, 273–275
- malignant pleural effusion, 277–280
- tracheostomy complications, 281–283
- retroperitoneal fibrosis, 161
- Richmond Agitation and Sedation Scale (RASS), 216
- risperidone, 217
- rituximab, 181
- rivaroxaban, 94
- romidepsin, 48
- sacral metastases, 237
- saddle sensory loss, 239
- salpingo-oophorectomy, 143
- scopolamine, 40
- scopolamine transdermal patch, 107
- secretory diarrhea
 - definition, 101
- seizure etiology
 - cancer patients, 250
- seizure management, 248–251
 - diagnosis, 249
 - HPI pearls, 248
 - imaging, 249
 - medication (and side-effects), 250
 - patient evaluation after first seizure episode, 248
 - physical examination pearls, 249
 - seizure incidence (main factors), 248
 - treatment, 250
- selective estrogen receptor modulator, 45
- sensory neuronopathy, 244
- sepsis, 187, 200
- septic shock, 199
- serotonin, 105
- serotonin reuptake inhibitors (SSRIs), 221
- serum amylase, 119
- serum viscosity, 75
- side-effects, 27, 29, 43
- sinus tachycardia (ST), 48
- sinus tachycardia segment elevated myocardial infarction (STEMI), 51, 54
- sinusoidal endothelial cells, 139
- sinusoidal obstruction syndrome (SOS), 139–140
 - clinical presentation, 139
 - death risk, 139
 - definition, 139
 - diagnostic criteria (Baltimore), 140
 - diagnostic criteria (modified Seattle), 140
 - incidence and mortality rate, 139
 - laboratory findings, 140
 - pathophysiology, 139
 - risk factors, 139
 - treatment, 140
- skin, 9, 181
- small molecule therapies, 21
 - examples, 21
- small molecule tyrosine kinase inhibitors, 45, 260
- small-cell lung cancer (SCLC), 243, 244
- sodium thiosulfate, 169–170
- solid tumors
 - likelihood of ICH, 228
- sorafenib, 21, 68, 122, 247
- spinal cord compression, 101
- spinal meningeal irritation, 232

- spine
 - most common tumors metastasizing to, 235
 - second most common site of osseous metastasis, 235
- splanchnic perfusion, 121
- splenomegaly, 192
- Staphylococcus aureus*, 278
- status epilepticus, 250
- stem-cell transplant, 4, 8, 49
- stenosis, 124, 270, 274, 282
- steroids, 86, 182, 192, 200, 229, 236
- stoma-related issues, 145
- stress, 203, 219
- stridor, 40, 86
- stroke in cancer patients, 253–256
 - cancer types associated with, 254
 - clinical presentation, 254
 - diagnostic imaging, 255
 - epidemiology, 253
 - etiology, 253
 - interval time (cancer diagnosis to stroke manifestation), 254
 - management, 255
 - pathophysiology, 253
 - risk (aggressiveness of cancer), 254
- subacute cerebellar degeneration, 243
- subarachnoid space, 232
- subclinical DIC, 65–66
- substem naming, 22
- sucralfate, 128
- sunitinib, 122
- superior mesenteric artery (SMA), 121, 124
- superior mesenteric vein, 121
- superior vena cava (SVC) syndrome, 85–87
 - death risk, 85
 - definition, 85
 - diagnostic imaging, 86
 - ED management, 86
 - malignancy predominant cause, 85
 - pathophysiology, 85
 - presentation, 86
 - treatment, 87
- supraventricular arrhythmias, 47
- supraventricular tachycardia (SVT), 48, 49
- surgery
 - definition, 4
- systemic endothelial disease, 139
- systemic sclerosis, 191
- systemic steroids, 175
- systemic therapy, 250
- systems-based overview
 - cancer complications, 43–46
 - systolic blood pressure, 79, 202
- T-cells, 193
- tachycardia, 49
- tachyphylaxis, 154
- tacrolimus, 193
- Takotsubo cardiomyopathy, 51, 52
- targeted cell therapy, 21–23
 - bispecific antibodies, 23
 - definition, 3
 - overview, 21
- targeted therapy
 - CVD complications, 45
- taxanes, 44
- thalidomide, 48, 122
- thecal sac, 235
- third nerve palsy, 224
- thoracentesis, 277, 279
- thoracic lesions, 236
- thrombocytopenia, 27, 51, 54, 65, 124, 139, 227–228, 253, 255–256, 264
 - ACS patients, 53
- thrombocytosis, 53
- thromboembolism, 118, 122
- thrombolysis, 256
- thromboprophylaxis, 91
- thrombosis, 51, 52, 85, 179
- thrombotic-fibrinolytic balance, 140
- thymoma, 86, 243
- thyroid, 179
- TIMI Risk Score, 54
- tisagenlecleucel, 14
- titration method, 27
- tocilizumab, 174, 176
- topoisomerase inhibitors, 5
- torsades de pointes (TdP), 48
 - type of ventricular arrhythmia, 47
- trachea, 269
- tracheal stoma, 281
- tracheo-esophageal prosthesis (TEP), 269–270
 - troubleshooting, 271
- tracheo-innominate fistula
 - definitive treatment, 283
 - pathophysiology, 283
 - risk factors, 11

Index

- tracheostomy
 definition, 281
 versus laryngectomy, 269
- tracheostomy complications, 281–283
 acute obstruction, 282
 bleeding (differential diagnosis), 282
 overview, 282
 patient assessment, 281
 physical examination, 281
 symptoms, 281
- tramadol, 26, 30
- transaminases, 140
- transfusion related acute lung injury (TRALI), 57
- transfusion related circulatory overload (TACO), 57
- transverse myelitis, 181
- trapezius, 82
- Trendelenburg positioning, 39
- tricyclic antidepressants, 240
- trigeminal nerve, 232
- troponin, 52, 69, 82, 92
- Trousseau sign, 208
- tumor
 definitions, 1
- tumor lysis syndrome (TLS), 195, 197, 207–209
 Cairo-Bishop definition, 207
 clinical presentation, 208
 definition, 207
 diagnosis, 208
 disposition, 209
 laboratory versus clinical, 207
 most common malignancies associated with, 207
 pathophysiology, 208
 physical examination pearls, 208
 risk, 207
 treatment, 209
- tylenol, 27
- typhlitis, *See* neutropenic enterocolitis
- tyrosine kinase inhibitor, 21
- ulcer formation, 169
- ulceration, 127
- ultrasonography
 compression ~ with Doppler, 91
- ultrasound, 124, 132, 148, 162
 point-of-care, 70, 79
- unfractionated heparin, 93
- ureteral stent, 163
- uric acid, 208
- urinary diversion, 165
- urinary dysfunction, 145
- urinary obstruction, 166
- urine color, 148
- urine osmolality, 158
- urine stasis, 149
- urogram, 148
- vagus nerve, 267
- vancomycin, 203
- vascular endothelial growth factor (VEGF), 22, 45, 122
- vascular occlusion, 118
- vasculitis, 118, 122, 136, 178
- vasopressors, 63, 174
- venlafaxine, 221
- venous plexus, 236
- venous sinus thrombosis, 247
- venous thromboembolism (VTE), 89–94
 anticoagulants (types), 93
 anticoagulation in patients with thrombocytopenia, 93
 anticoagulation therapy contraindications, 93
 cancer-related deaths (second most common cause), 89
 definition, 89
 diagnosis (risk stratification scores), 90
 gynecologic oncology surgery complications, 144
 hospitalized patients, 89
 imaging, 91
 Khorana scores (cancer outpatients), 91
 laboratory analysis, 91
 mortality risk, 89
 pathophysiology, 89
 patients with renal insufficiency, 94
 postoperative, 89
 risk factors in gynecologic oncology patients, 144
 treatment, 92
- ventricular arrhythmias, 44, 46, 47, 49
- ventricular tachycardia (VT), 45, 48–49, 154
- vertebral bone metastasis, 236
- vesicant chemotherapy extravasation, 169

- vinca alkaloids, 44, 118, 156
 vesicating chemotherapy agents, 170
- Virchow's triad, 89
- viscosity
 definition, 73
- viscous lidocaine, 128
- vitamin K antagonists, 93
- vorinostat, 23, 48
- VSP inhibitors
 heart failure as side-effect, 68
- Waldenstrom macroglobulinemia, 73
- warfarin, 93
- Wells and Revised Geneva score, 90
- World Health Organization Oral
 Toxicity Scale, 128
- X-ray, 124, 133, 180
- xyloxylin, 128
- zoledronic acid, 154